Home › NDC Lookup › RxCUI directory › RxCUI 2626385

Fingolimod 0.5 MG Disintegrating Oral Tablet [Tascenso] — RxCUI 2626385

RxNorm drug concept · Semantic branded drug
RxCUI 2626385 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2626385
Official nameFingolimod 0.5 MG Disintegrating Oral Tablet [Tascenso]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asTascenso 0.5 MG Disintegrating Oral Tablet; Tascenso ODT 0.5 MG Disintegrating Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)39 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Fingolimod: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. It is approved for pe...
  • Take it by mouth once a day, with or without food. If you have Tascenso ODT, place it on your tongue and let it dissolve. Follow your prescriber's directions exactly.
  • Fingolimod can slow your heart rate and cause heart block, mostly in the first 6 hours. We check your pulse, blood pressure and ECG. Some people need overnight monitoring. This may...
  • Why do I have to be watched after the first dose?
📖 Read our full Fingolimod guide →

🕸️ Concept Web — How Fingolimod 0.5 MG Disintegrating Oral Tablet [Ta... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Fingolimod 0.5 MG Disintegrating Oral Tablet [Tascenso] RxCUI 2626385

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Fingolimod 1012892
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Tascenso 2610296
  3. Dose forms 12

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Fingolimod Disintegrating Oral Tablet 2610294
    • Fingolimod Disintegrating Oral Product 2610293
    • Fingolimod Oral Product 1165017
    • Fingolimod Pill 1165018
    • Fingolimod Disintegrating Oral Tablet [Tascenso] 2610301
    • Tascenso Disintegrating Oral Product 2610300
    • Tascenso Oral Product 2610298
    • Tascenso Pill 2610299
    • +4 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Fingolimod 0.5 MG Disintegrating Oral Tablet SCD · 2626383
  • Fingolimod 0.5 MG SCDC · 1012893
  • Fingolimod Disintegrating Oral Tablet SCDF · 2610294
  • Fingolimod Disintegrating Oral Product SCDG · 2610293
  • Fingolimod Oral Product SCDG · 1165017
  • Fingolimod Pill SCDG · 1165018

Brand-Name Concepts

  • Fingolimod 0.5 MG [Tascenso] SBDC · 2626384
  • Fingolimod Disintegrating Oral Tablet [Tascenso] SBDF · 2610301
  • Tascenso Disintegrating Oral Product SBDG · 2610300
  • Tascenso Oral Product SBDG · 2610298
  • Tascenso Pill SBDG · 2610299
  • Tascenso BN · 2610296

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2626385 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70709-0062-30 3 BLISTER PACK in 1 CARTON (70709-062-30) / 10 TABLET, ORAL... TASCENSO ODT Cycle Pharmaceuticals Ltd 2023-02-01
70709-0065-30 3 BLISTER PACK in 1 CARTON (70709-065-30) / 10 TABLET, ORAL... TASCENSO ODT Cycle Pharmaceuticals Ltd 2023-02-01
Observed labelers: Cycle Pharmaceuticals Ltd (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.